This work from Quirin Zangle, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
John Kirkwood, MD, PhD, addresses the idea of pseudoprogression seen in melanoma therapy.
An expert in melanoma cancer treatment relays the monitoring options for melanoma therapy and gives advice for how long these therapies should be monitored.
CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.
A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.
Dr Roy Herbst reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.
Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.
Patients with high-risk smoldering myeloma who were treated with carfilzomib, lenalidomide, and dexamethasone and lenalidomide maintenance experienced an improvement in minimal residual disease–negative complete response and could have delayed end-organ disease.